1.0UEFConnecthttps://uefconnect.uef.fi/en/Astrid Subrizi (astrid.subrizi@uef.fi) - UEFConnectrich600338<blockquote class="wp-embedded-content" data-secret="MA6QGYpun8"><a href="https://uefconnect.uef.fi/en/astrid.subrizi">Astrid Subrizi (astrid.subrizi@uef.fi)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://uefconnect.uef.fi/en/astrid.subrizi/embed/#?secret=MA6QGYpun8" width="600" height="338" title="“Astrid Subrizi (astrid.subrizi@uef.fi)” — UEFConnect" data-secret="MA6QGYpun8" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://uefconnect.uef.fi/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
I study and develop ocular drug delivery systems. I am interested in the design and functionality of nanocarriers, in the selection of targeting moieties that facilitate safe and precise delivery of drugs to ocular tissues, and in the investigation of ocular barriers and their effects on ocular pharmacokinetics.